Page 1 | Search Results | Blood | American Society of Hematology

1-14 of 14

Sort by

Sort Order Select

Journal Articles

FT576: Multi-Specific Off-the-Shelf CAR-NK Cell Therapy Engineered for Enhanced Persistence, Avoidance of Self-Fratricide and Optimized Mab Combination Therapy to Prevent Antigenic Escape and Elicit a Deep and Durable Response in Multiple Myeloma

Jode P Goodridge, PhD, Ryan Bjordahl, PhD, Sajid Mahmood, PhD, John Reiser, PhD, Svetlana Gaidarova, MS, Robert Blum, MS, Frank Cichocki, PhD, Hui-yi Chu, PhD, Greg Bonello, PhD, Tom Lee, PhD, Brian Groff, Miguel Meza, BS, Yu-Waye Chu, MD, Bruce Walcheck, PhD, Karl-Johan Malmberg, MD PhD, Jeffrey S. Miller, MD, Armin Rehm, Uta Hopken, Bahram Valamehr, PhD

Blood (2020) 136 (Supplement 1): 4–5.

https://doi.org/10.1182/blood-2020-142750

Published: 2020

Journal Articles

Systems-Level Analysis of the Immune Repertoire in Neutropenia Reveal Arrested NK Cell Differentiation and Exhaustion

Ebba Sohlberg, Aline Pfefferle, PhD, Eivind Heggernes Ask, MD, Astrid Tschan-Plessl, MD, Benedikt Jacobs, MD, Suzanne Lorenz, PhD, Stephan Meinke, Petter Hoglund, MD PhD, Mikael Sundin, MDPhD, Goran Karlsson, MDPhD, Jan Palmblad, MD PhD, Karl-Johan Malmberg, MD PhD

Blood (2020) 136 (Supplement 1): 24–25.

https://doi.org/10.1182/blood-2020-141981

Published: 2020

Journal Articles

CAR19 iPSC-Derived NK Cells Utilize the Innate Functional Potential Mediated through NKG2A-Driven Education and Override the HLA-E Check Point to Effectively Target B Cell Lymphoma

Blood (2020) 136 (Supplement 1): 34–35.

https://doi.org/10.1182/blood-2020-138527

Published: 2020

Journal Articles

Innate-like Chemokine Receptor Profile and Migratory Behaviour By Terminally Differentiated and Educated NK Cells

Mieszko Lachota, Daniel Alfredo Palacios, MSc, Dennis Clement, MSc, Eivind Heggernes Ask, MD, Hanna Julie Hoel, MSc, Merete Thune Wiiger, PhD, Marianna Vincenti, MD, Magdalena Winiarska, Radoslaw Zagozdzon, MD PhD, Karl-Johan Malmberg, MD PhD

Blood (2020) 136 (Supplement 1): 24–25.

https://doi.org/10.1182/blood-2020-140944

Published: 2020

Journal Articles

FT538: Preclinical Development of an Off-the-Shelf Adoptive NK Cell Immunotherapy with Targeted Disruption of CD38 to Prevent Anti-CD38 Antibody-Mediated Fratricide and Enhance ADCC in Multiple Myeloma When Combined with Daratumumab

Ryan Bjordahl, PhD, Svetlana Gaidarova, MS, Karrune Woan, MD PhD, Frank Cichocki, PhD, Greg Bonello, PhD, Megan Robinson, Chelsea Ruller, Mochtar Pribadi, PhD, Jason Dinella, PhD, Lauren Fong, PhD, Janel Huffman, MS, Hui-yi Chu, PhD, Tom Lee, PhD, Ramzey Abujarour, PhD, Dan S Kaufman, MD PhD, Karl-Johan Malmberg, MD PhD, Jeffrey S. Miller, MD, Bahram Valamehr, PhD

Blood (2019) 134 (Supplement_1): 133.

https://doi.org/10.1182/blood-2019-131138

Published: 2019

Journal Articles

FT596: Translation of First-of-Kind Multi-Antigen Targeted Off-the-Shelf CAR-NK Cell with Engineered Persistence for the Treatment of B Cell Malignancies

Jode P Goodridge, PhD, Sajid Mahmood, PhD, Huang Zhu, PhD, Svetlana Gaidarova, MS, Robert Blum, Ryan Bjordahl, PhD, Frank Cichocki, PhD, Hui-yi Chu, PhD, Greg Bonello, PhD, Tom Lee, PhD, Brian Groff, Miguel Meza, BS, Bruce Walcheck, PhD, Karl-Johan Malmberg, MD PhD, Jeffrey S. Miller, MD, Dan S Kaufman, MD PhD, Bahram Valamehr, PhD

Blood (2019) 134 (Supplement_1): 301.

https://doi.org/10.1182/blood-2019-129319

Published: 2019

Journal Articles

System-Level Disease-Driven Immune Signatures in Patients with Diffuse Large B-Cell Lymphoma Associated with Poor Survival

Astrid Tschan-Plessl, MD, Eivind Heggernes Ask, Thea Johanne Gjerdingen, Michelle Saetersmoen, Hanna Julie Hoel, Merete Thune Wiiger, Msc, Johanna Olweus, Björn E Wahlin, MD PhD, Amir Horowitz, PhD, Todd A Fehniger, MD PhD, Harald Holte, MD PhD, Arne Kolstad, MD PhD, Karl-Johan Malmberg, MD PhD

Blood (2019) 134 (Supplement_1): 2897.

https://doi.org/10.1182/blood-2019-131359

Published: 2019

Journal Articles

CD38-Deficient, CD16-Engineered NK Cells Exhibit Enhanced Antibody-Dependent Cellular Cytotoxicity without NK Cell Fratricide to Augment Anti-Myeloma Immunity in Combination with Daratumumab

Karrune Woan, MD PhD, Ryan Bjordahl, PhD, Frank Cichocki, PhD, Svetlana Gaidarova, MS, Cameron Pride, BS, Dan S Kaufman, MD PhD, Karl-Johan Malmberg, MD PhD, Sarah Cooley, MD, Bahram Valamehr, PhD, Jeffrey S. Miller, MD

Blood (2018) 132 (Supplement 1): 3224.

https://doi.org/10.1182/blood-2018-99-116459

Published: 2018

Journal Articles

KIR Expression on in Vitro -Derived Natural Killer Cells Does Not Regulate Killing of Allogeneic Targets

Yunzu Michele Wang, MD, Huang Zhu, PhD, Alessa Ruiz-Cisneros, Naveen Heragu, BS, Eivind Heggernes Ask, Hanna Julie Hoel, Karl-Johan Malmberg, MD PhD, Dan S Kaufman, MD PhD

Blood (2018) 132 (Supplement 1): 3705.

https://doi.org/10.1182/blood-2018-99-117151

Published: 2018

Journal Articles

Notch Activation Rescues Exhaustion in CISH -Deleted Human iPSC-Derived Natural Killer Cells to Promote In Vivo Persistence and Enhance Anti-Tumor Activity

Huang Zhu, PhD, Robert Blum, Zhengming Wu, Andres Bahena, Hanna Julie Hoel, Eivind Heggernes Ask, Kun-Liang Guan, PhD, Karl-Johan Malmberg, MD PhD, Dan S Kaufman, MDPhD

Blood (2018) 132 (Supplement 1): 1279.

https://doi.org/10.1182/blood-2018-99-112791

Published: 2018

Journal Articles

Efficient Scale-up and Pre-Clinical Evaluation of NKG2C+ Adaptive NK Cell Expansion for Therapy Against High-Risk AML/MDS

Blood (2018) 132 (Supplement 1): 195.

https://doi.org/10.1182/blood-2018-195

Published: 2018

Journal Articles

Induced Pluripotent Stem Cell-Derived NK Cells Genetically Modified to Express NKG2C/DAP12 Mediate Potent Function When Targeted through an NKG2C/IL-15/CD33 Tri-Specific Killer Engager (TriKE)

Emily Chiu, PhD, Frank Cichocki, PhD, Martin Felices, PhD, Sarah Cooley, MD, Helen Chu, PhD, Moyar Q. Ge, PhD, Ryan Bjordahl, PhD, Dan S Kaufman, MD PhD, Karl-Johan Malmberg, MD PhD, Bahram Valamehr, PhD, Jeffrey S. Miller, MD

Blood (2018) 132 (Supplement 1): 729.

https://doi.org/10.1182/blood-2018-99-112202

Published: 2018

Journal Articles

Complete Remission and Signs of Immunoediting Following Haploidentical NK Cell Therapy in Refractory High-Risk MDS and AML Ell Therapy in Refractory High-Risk MDS and AML

Andreas T Björklund, MD PhD MSc, Mattias Carlsten, MD PhD, Ebba Sohlberg, PhD, Trevor Clancy, Lisa Liu, Mohsen Karimi, PhD, Sarah Cooley, MD, Jeffrey S. Miller, MD, Emma Watz, Björn Engelbrekt Wahlin, Marzia Palma, MD PhD, Lotta Hansson, Per Ljungman, Eva Hellstrom-Lindberg, MD PhD, Hans-Gustaf Ljunggren, Karl-Johan Malmberg, MD PhD

Blood (2017) 130 (Supplement 1): 4458.

https://doi.org/10.1182/blood.V130.Suppl_1.4458.4458

Published: 2017

Journal Articles

Early and Transient Microchimerism Associated with Complete Remission after Adoptively Transferred Haploidentical NK Cells Against High Risk Myelodysplastic Syndrome and Refractory Acute Myeloid Leukemia

Andreas T Björklund, MDPhD, Mattias Carlsten, MD PhD, Marie Schaffer, PhD, Lisa Liu, MD, Sarah A. Cooley, MD MS, Jeffrey S. Miller, MD, Emma Watz, MD, Marzia Palma, MD PhD, Lotta Hansson, MD PhD, Björn E Wahlin, MD PhD, Lars Möllgård, MDPhD, Hans Hagglund, MD PhD, Pontus Blomberg, PhD, Per T. Ljungman, MD PhD, Eva Hellström-Lindberg, MD PhD, Hans-Gustaf Ljunggren, MD PhD, Karl-Johan Malmberg, MD, PhD

Blood (2014) 124 (21): 1120.

https://doi.org/10.1182/blood.V124.21.1120.1120

Published: 2014

NARROW

FT576: Multi-Specific Off-the-Shelf CAR-NK Cell Therapy Engineered for Enhanced Persistence, Avoidance of Self-Fratricide and Optimized Mab Combination Therapy to Prevent Antigenic Escape and Elicit a Deep and Durable Response in Multiple Myeloma

Systems-Level Analysis of the Immune Repertoire in Neutropenia Reveal Arrested NK Cell Differentiation and Exhaustion

CAR19 iPSC-Derived NK Cells Utilize the Innate Functional Potential Mediated through NKG2A-Driven Education and Override the HLA-E Check Point to Effectively Target B Cell Lymphoma

Innate-like Chemokine Receptor Profile and Migratory Behaviour By Terminally Differentiated and Educated NK Cells

FT538: Preclinical Development of an Off-the-Shelf Adoptive NK Cell Immunotherapy with Targeted Disruption of CD38 to Prevent Anti-CD38 Antibody-Mediated Fratricide and Enhance ADCC in Multiple Myeloma When Combined with Daratumumab

FT596: Translation of First-of-Kind Multi-Antigen Targeted Off-the-Shelf CAR-NK Cell with Engineered Persistence for the Treatment of B Cell Malignancies

System-Level Disease-Driven Immune Signatures in Patients with Diffuse Large B-Cell Lymphoma Associated with Poor Survival

CD38-Deficient, CD16-Engineered NK Cells Exhibit Enhanced Antibody-Dependent Cellular Cytotoxicity without NK Cell Fratricide to Augment Anti-Myeloma Immunity in Combination with Daratumumab

KIR Expression on in Vitro -Derived Natural Killer Cells Does Not Regulate Killing of Allogeneic Targets

Notch Activation Rescues Exhaustion in CISH -Deleted Human iPSC-Derived Natural Killer Cells to Promote In Vivo Persistence and Enhance Anti-Tumor Activity

Efficient Scale-up and Pre-Clinical Evaluation of NKG2C+ Adaptive NK Cell Expansion for Therapy Against High-Risk AML/MDS

Induced Pluripotent Stem Cell-Derived NK Cells Genetically Modified to Express NKG2C/DAP12 Mediate Potent Function When Targeted through an NKG2C/IL-15/CD33 Tri-Specific Killer Engager (TriKE)

Complete Remission and Signs of Immunoediting Following Haploidentical NK Cell Therapy in Refractory High-Risk MDS and AML Ell Therapy in Refractory High-Risk MDS and AML

Early and Transient Microchimerism Associated with Complete Remission after Adoptively Transferred Haploidentical NK Cells Against High Risk Myelodysplastic Syndrome and Refractory Acute Myeloid Leukemia

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only